Clinical Trial Update: STOP-HER2: Stopping Trastuzumab in HER2+ MBC [Phase 2]

View source ↗

Summary

Clinical trial update indicating the STOP-HER2 Phase 2 study investigating stopping trastuzumab in HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING